LEVI vs REGN · P/E 17, rev $6.36B vs P/E 14, rev $14.34B
Levi Strauss & Co Class A (LEVI) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
Levi Strauss & Co Class A (LEVI) is a apparel manufacturing company listed on NYSE.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Latest reported LEVI revenue for 2024-12-01 was $6.36B. Net income was $210.6M. Revenue was up 2.9% from 2023-11-26 to 2024-12-01. LEVI currently screens at market cap $9.00B and trailing P/E 17.2.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
LEVI currently screens at market cap $9.00B and trailing P/E 17.2. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the LEVI and REGN stock pages for the full models.
Not investment advice.